Of these, HER3 is the most likely candidate because of its involvement in resistance mechanisms in other cancer types, including trastuzumab-induced resistance in breast cancer and resistance to MEK inhibition in KRAS-mutant lung and colon cancer [29, 30]. Here, ERBB3 is linked to breast cancer.